Comment from AIGM Inc
AnonymousOpposeBusiness
Summary: AIGM Inc., an AI-driven drug discovery company, opposes the proposed withdrawal of TAVNEOS (avacopan) from the market. They argue that the drug's hepatotoxicity is a result of its specific physicochemical properties rather than a liability of the C5aR1 target, and they recommend label restrictions instead of a full withdrawal.
We submit this comment on behalf of AIGM Inc. (Delaware, USA), an AI-driven drug discovery company. Our cheminformatic analysis of the C5aR1 chemical space in ChEMBL 36 provides evidence that avacopan's hepatotoxicity is compound-specific (aLogP 5.31, MW 581.7 Da, biliary accumulation), not a C5aR1 target-level liability. 15 safer C5aR1 inhibitor candidates were identified. We recommend label restriction rather than market withdrawal. Full analysis attached.